Astellas Pharma
Stock Forecast, Prediction & Price Target
Astellas Pharma Financial Estimates
Astellas Pharma Revenue Estimates
Astellas Pharma EBITDA Estimates
Astellas Pharma Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 3/31/2022 | 3/31/2023 | 3/31/2024 | 3/31/2026 | 3/31/2027 | 3/31/2028 | 3/31/2029 |
Revenue
% change YoY
| $1.29T N/A | $1.51T 17.16% | $1.60T 5.60% | Avg: $1.62T Low: $1.62T High: $1.62T avg. 1.18% | Avg: $1.74T Low: $1.74T High: $1.74T avg. 7.51% | Avg: $1.73T Low: $1.73T High: $1.73T avg. -0.59% | Avg: $1.51T Low: $1.51T High: $1.51T avg. -12.46% |
Net Income
% change YoY
| $124.08B N/A | $98.71B -20.44% | $17.04B -82.73% | Avg: $115.04B Low: $73.69B High: $154.58B avg. 574.93% | Avg: $183.29B Low: $183.29B High: $183.29B avg. 59.32% | Avg: $218.63B Low: $218.63B High: $218.63B avg. 19.28% | Avg: $142.85B Low: $142.85B High: $142.85B avg. -34.66% |
EBITDA
% change YoY
| $299.70B N/A | $246.87B -17.62% | $194.81B -21.08% | Avg: $396.91B Low: $396.91B High: $396.91B avg. 103.73% | Avg: $426.74B Low: $426.74B High: $426.74B avg. 7.51% | Avg: $424.21B Low: $424.21B High: $424.21B avg. -0.59% | Avg: $371.33B Low: $371.33B High: $371.33B avg. -12.46% |
EPS
% change YoY
| $67.08 N/A | $54.24 -19.14% | $9.47 -82.54% | Avg: $63.92 Low: $40.95 High: $85.9 avg. 575.02% | Avg: $101.85 Low: $101.85 High: $101.85 avg. 59.32% | Avg: $121.49 Low: $121.49 High: $121.49 avg. 19.28% | Avg: $79.38 Low: $79.38 High: $79.38 avg. -34.66% |
Operating Expenses
% change YoY
| $794.85B N/A | $906.4B 14.03% | $1.28T 41.84% | Avg: $677.42B Low: $677.42B High: $677.42B avg. -47.30% | Avg: $728.34B Low: $728.34B High: $728.34B avg. 7.51% | Avg: $724.01B Low: $724.01B High: $724.01B avg. -0.59% | Avg: $633.77B Low: $633.77B High: $633.77B avg. -12.46% |
FAQ
What is Astellas Pharma stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 154.72% in 2026-2029.
We have gathered data from 2 analysts. Their low estimate is 73.69B, average is 115.04B and high is 154.58B.
What is Astellas Pharma stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of -1.08% in 2026-2029.
We have gathered data from 1 analysts. Their low revenue estimate is $1.62T, average is $1.62T and high is $1.62T.
What is Astellas Pharma stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 154.74% in 2026-2029.
We have gathered data from 2 analysts. Their low earnings per share estimate is $40.95, average is $63.92 and high is $85.89.